Latest / Bloomberg Intelligence / Disney Taps Parks Chief Josh D’Amaro to Succeed Iger as CEO
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, podcasts, radio news. You're listening to the
- 0:10Speaker 1: Bloomberg Intelligence podcast. Catch us live weekdays at ten am
- 0:14Speaker 1: Eastern on Apple, Cocklay and Android Auto with the Bloomberg
- 0:17Speaker 1: Business app. Listen on demand wherever you get your podcasts,
- 0:21Speaker 1: or watch us live on YouTube.
- 0:23Speaker 2: Walt Disney saying that Josh Tomorrow will succeed Bob Iger
- 0:27Speaker 2: as CEO of the company. This ends a three year
- 0:30Speaker 2: search to replace its long serving leader, who had to
- 0:33Speaker 2: come back after the first time around didn't quite work out.
- 0:37Speaker 3: Let's bring in Githa Ranganathen.
- 0:38Speaker 2: She is our US media analyst here at Bloomberg Intelligence.
- 0:41Speaker 2: And I want to contrast what happened this time around
- 0:44Speaker 2: with the succession planning Githa, with what happened in the
- 0:47Speaker 2: past when Bob Chapek, also of the Parks division, was
- 0:51Speaker 2: named CEO but didn't last too long on the job.
- 0:54Speaker 2: Can you compare and contrast the different succession efforts.
- 0:59Speaker 4: Yeah, I think it was a very different time Scarlet.
- 1:01Speaker 4: So remember he was appointed in February of twenty twenty.
- 1:06Speaker 4: March twenty twenty, everything closes down, including you know, Disney
- 1:10Speaker 4: Parks because of the pandemic. So it was kind of unfortunate.
- 1:14Speaker 4: The timing was all wrong, I would say for Bob Chapek.
- 1:18Speaker 4: And what happened then is, of course, you know, movies
- 1:21Speaker 4: were shut down a big part of Disney's business, movies
- 1:24Speaker 4: as well as the parks again. But then what really
- 1:27Speaker 4: kind of shot into prominence at that point was the
- 1:29Speaker 4: streaming business, a business that Bob Chapik was not really
- 1:33Speaker 4: very familiar with, and while he did have some experience
- 1:36Speaker 4: in content, obviously it was not enough. And we had
- 1:39Speaker 4: a whole bunch of different missteps with the content part
- 1:44Speaker 4: of the business, which kind of led to the whole
- 1:47Speaker 4: you know mess that we saw, you know follow I
- 1:51Speaker 4: think this time we were in a very very different position.
- 1:54Speaker 4: I think at that point Disney was still kind of
- 1:55Speaker 4: trying to figure out what it really was. Was it
- 1:57Speaker 4: a TV company, was it a studio, was it a
- 1:59Speaker 4: theme park company? Or was it really a streaming player?
- 2:01Speaker 4: And I think now the pieces have kind of fallen
- 2:03Speaker 4: in place. We are on much more steady ground. I
- 2:07Speaker 4: would say, you know, they have their clear mandates, whether
- 2:09Speaker 4: it isn't streaming, whether it's in studio, you know, the
- 2:13Speaker 4: clear what has really emerged clearly right now Scarlett is
- 2:16Speaker 4: that parks is the main core growth engine of the company,
- 2:20Speaker 4: and I think that is reflected in this choice today
- 2:22Speaker 4: with Josh Tomorrow.
- 2:24Speaker 5: So Keithan.
- 2:24Speaker 6: Josh is a twenty eight year veteran of Disney running
- 2:28Speaker 6: the parks. But of course the other big part of
- 2:31Speaker 6: the company is it's you know, entertainment business. Dana Walden
- 2:37Speaker 6: who runs the big part of that business, great reputation
- 2:40Speaker 6: in Hollywood. It's important to keep her at the Walt
- 2:44Speaker 6: Disney Company.
- 2:45Speaker 5: Are they going to be able to do that?
- 2:48Speaker 4: I absolutely think so. So, you know, they obviously this
- 2:50Speaker 4: was a very clever move by the board to kind
- 2:53Speaker 4: of create this new role for Dana Walden, make her
- 2:56Speaker 4: the president and the chief creative officer. They've never had
- 2:59Speaker 4: this before, but they specifically created this one for Dana Walden,
- 3:03Speaker 4: so that I think really kind of I think dispels
- 3:07Speaker 4: a lot of fears about what would happen from a
- 3:09Speaker 4: creative perspective. You know, last time, this was the same
- 3:13Speaker 4: problem that you know, many investors raised when Bob Japek
- 3:16Speaker 4: became CEO. So having her there in the creative role
- 3:19Speaker 4: I think definitely plays very well with Hollywood, with the
- 3:22Speaker 4: creative community. And ensures that, you know, Disney will still
- 3:25Speaker 4: have a top tier content coming to its streaming platforms
- 3:29Speaker 4: for the foreseeable future.
- 3:31Speaker 2: So Josh Deamarrow takes the job on March eighteenth, that's
- 3:36Speaker 2: when the succession is effective. And we talked about how
- 3:39Speaker 2: yesterday Disney came out with a forecast that was fairly tepid,
- 3:42Speaker 2: and one way of looking at that is it kind
- 3:44Speaker 2: of you know, clears the deck.
- 3:46Speaker 3: Lets him start off with the clean say.
- 3:48Speaker 2: And set expectations and kind of manage it for investors
- 3:51Speaker 2: a way that he sees fit. At what point does
- 3:54Speaker 2: he own everything that happens to Disney.
- 3:58Speaker 4: So actually a lot of the things that we're seeing
- 4:00Speaker 4: right now with the Parks has been under Josh Tomorrow's watch.
- 4:04Speaker 4: Remember once Bob Chapek was promoted to the CEO position,
- 4:10Speaker 4: Josh Tomorrow assumed the role of chief of the Parks,
- 4:14Speaker 4: and so all of the different initiatives that we've seen,
- 4:16Speaker 4: you know, whether it's Lightning Lane, whether it's Genie, whether
- 4:19Speaker 4: it's the sixty billion dollar expansion, a lot of that
- 4:22Speaker 4: has been you know Josh Tomorrow's doing. So yeah, I mean,
- 4:26Speaker 4: of course we're you know, I think the street is
- 4:28Speaker 4: definitely going to give him a few quarters to kind
- 4:30Speaker 4: of settle in, But he has pretty much been the architect,
- 4:33Speaker 4: along with Barb Aiger, I'm sure and the rest of
- 4:35Speaker 4: you know, the management team in kind of instituting the
- 4:38Speaker 4: strategy and making the parks a prominent, you know, part
- 4:42Speaker 4: of the portfolio going forward. So very soon, you know,
- 4:46Speaker 4: the short answer, Scarlett is very soon. I think he
- 4:48Speaker 4: owns pretty much all of this right away.
- 4:50Speaker 6: In fact, Keith I five Josh Tomorrow, day one of
- 4:53Speaker 6: my tenure CEO. I would go and I would say, hey,
- 4:57Speaker 6: explain to me why we are not spinning out are
- 5:00Speaker 6: broadcasting cable networks. They are businesses that are in a
- 5:03Speaker 6: secular decline. They're dragging down our multiple Let's cut them loose.
- 5:07Speaker 6: Do you think that's even an option for the Walt
- 5:09Speaker 6: Disney Company.
- 5:11Speaker 4: I think it is. I think everybody is considering that
- 5:14Speaker 4: right now. I mean we've just seen what you know,
- 5:17Speaker 4: Warner Brothers Discovery has been able to achieve by kind
- 5:20Speaker 4: of separating out it's a studio and streaming from the
- 5:22Speaker 4: TV network's business. So I definitely would not rule that out.
- 5:26Speaker 4: I'm sure Disney will consider and Josh Tomorrow will consider
- 5:29Speaker 4: all options once he becomes CEO.
- 5:33Speaker 2: What happens to Jimmy Pataro over at ESPN, I mean,
- 5:37Speaker 2: does that become part of the spinouts as Paul was
- 5:39Speaker 2: talking about it, Because there's different parts of Disney's media
- 5:42Speaker 2: business that are slowing down that are no longer the
- 5:44Speaker 2: crown rules the way they once were, whether you're talking
- 5:47Speaker 2: about the network television, or whether you're talking about ESPN,
- 5:50Speaker 2: or whether you're talking about the movie business.
- 5:53Speaker 4: Yeah, I think sports is still very core to Disney.
- 5:56Speaker 4: I mean they are so if you just kind of
- 5:58Speaker 4: look at the US sports landscape, ESPN actually owns majority
- 6:02Speaker 4: of the marquee US sports right almost about forty percent
- 6:06Speaker 4: of all sports viewing happens on ESPN platforms. So obviously
- 6:10Speaker 4: it's still very core to the company. As far as
- 6:12Speaker 4: Jimmy Pittaro is concerned. Scarlett, I mean, yes, he was
- 6:15Speaker 4: one of the you know, candidates that they were considering
- 6:19Speaker 4: to take on this job, but I think he himself
- 6:21Speaker 4: had many times indicated that he was not really interested
- 6:24Speaker 4: in the top spot. I think he kind of carries
- 6:26Speaker 4: on business as usual with ESPN. You know, it's a
- 6:29Speaker 4: little bit of a wait and watch what exactly happens
- 6:31Speaker 4: with the strategy. It is really instrumental, I think, to
- 6:34Speaker 4: their streaming business because you know, as they kind of
- 6:37Speaker 4: mentioned even yesterday on their earnings call, you know a
- 6:40Speaker 4: lot of people taking the bundle, the ESPN streaming plus
- 6:43Speaker 4: the Disney plus the Hulle. So it is a critical
- 6:45Speaker 4: portion of that. So I'm not really sure how exactly
- 6:48Speaker 4: a spinout Wood would work. But of course, again, you know,
- 6:52Speaker 4: we are in a very very different time and age,
- 6:55Speaker 4: and everybody is thinking about all possible options when it
- 6:58Speaker 4: comes to a media.
- 7:00Speaker 5: Stay with us. More from Bloomberg Intelligence coming up after this.
- 7:07Speaker 1: You're listening to the Bloomberg Intelligence podcast. Catch us live
- 7:11Speaker 1: weekdays at ten am Eastern on Applecarcklay and Android Auto
- 7:14Speaker 1: with the Bloomberg Business App. Listen on demand wherever you
- 7:17Speaker 1: get your podcasts, or watch us live on YouTube.
- 7:21Speaker 6: PayPal Holding said HP chief executive officer Enrique Lauris will
- 7:27Speaker 6: take the top job from Alex Chris, whose turnaround plan
- 7:30Speaker 6: failed to meet targets and streamline the payments business. The
- 7:33Speaker 6: stocks down nineteen percent today, fifty two week low, off
- 7:37Speaker 6: twenty seven percent year to date, off over fifty percent
- 7:40Speaker 6: over the trailing twelve months. This is a name I
- 7:43Speaker 6: thought at the beginning of this whole fintech thing that
- 7:45Speaker 6: this had This was a company that could really be
- 7:47Speaker 6: a leader there, but that has not been the case.
- 7:49Speaker 5: Dick sa Garrett joins us.
- 7:50Speaker 6: She's a senior fintech and payments analyst for Bloomberg Intelligence Dix.
- 7:54Speaker 5: Not a good day for PayPal. What's going on here?
- 7:59Speaker 7: Yeah, definitely right, like two big headlines. Hit At once
- 8:03Speaker 7: missed four Q expectations and then announced a CEO change.
- 8:07Speaker 7: So on the print side, adjusted EPs was about a
- 8:11Speaker 7: four percent miss and the revenue came in one percent lower,
- 8:15Speaker 7: and I should highlight this is like their first miss
- 8:17Speaker 7: in two years. But I think the bigger issue is
- 8:20Speaker 7: forward looking branded checkout, which is the main core high
- 8:25Speaker 7: margin business for PayPal that has slowed to one percent
- 8:28Speaker 7: in the fourth quarter. And PayPal is also flagging in
- 8:32Speaker 7: earnings decline for twenty twenty six, So those were the
- 8:34Speaker 7: key forward looking problem areas, and the CEO change definitely
- 8:40Speaker 7: was a surprise. I mean, the guidance division was driven
- 8:42Speaker 7: by their investments in some of the merchant business that
- 8:47Speaker 7: they're doing, but I think the market reaction goes beyond that.
- 8:53Speaker 7: I think it goes more around some of the serious
- 8:56Speaker 7: gaps that appear to have been discovered actually with Apple
- 9:00Speaker 7: Bay and all the product advancements that the competition has
- 9:04Speaker 7: come through, and I think, yeah, lots to unpack there today.
- 9:08Speaker 6: So just give us a sense of the competitive landscape
- 9:11Speaker 6: of the businesses that paypals and the financial technology and
- 9:14Speaker 6: kind of where do they fit in what are they
- 9:16Speaker 6: maybe not doing right here?
- 9:19Speaker 7: So PayPal has two parts of the ecosystem. It works
- 9:24Speaker 7: with the merchants where you see the PayPal button when
- 9:26Speaker 7: you check out, and it works with the consumers through
- 9:28Speaker 7: its app, the PayPal app and the Venmo app. What
- 9:33Speaker 7: is very interesting is that management kept highlighting execution, discipline
- 9:38Speaker 7: and prioritization, but honestly, like that is the main game.
- 9:42Speaker 7: PayPal's biggest A value ad is the two sided network.
- 9:46Speaker 7: They could not have afforded to either drop the merchant
- 9:50Speaker 7: or forget about the consumer. So it's been like it's
- 9:53Speaker 7: a very competitive landscape. You have Stripe, Aden, Apple, pay
- 9:58Speaker 7: Is you would have noticed recently revised their partnership from
- 10:03Speaker 7: they moved from Goldman's to JP Morgan. So everyone is
- 10:06Speaker 7: charging first there and PayPal needs to show up on
- 10:09Speaker 7: that and I thought they were getting that. But I
- 10:12Speaker 7: think this new CEO to change definitely puts a multi
- 10:16Speaker 7: year transformation back in the play now.
- 10:18Speaker 6: So what do you think is the is the next
- 10:21Speaker 6: step for this company here? I mean a can of
- 10:25Speaker 6: kind of remain competitive in this business going forward? Does
- 10:28Speaker 6: it need to think about a new structure or a
- 10:31Speaker 6: new strategy.
- 10:32Speaker 5: What do you think needs to happen here?
- 10:34Speaker 7: Yeah, that's the million dollar question, Paul. I think so
- 10:36Speaker 7: there are two things. One is, I think investors need
- 10:39Speaker 7: really need clarity now on how PayPal reaccelerates hiscore checkout business.
- 10:43Speaker 7: Is it conversion, is it pricing merchant value proposition, because
- 10:48Speaker 7: that's still the core engine. But I think secondly is
- 10:51Speaker 7: whether the new leadership really signals of broader strategic shakeup,
- 10:55Speaker 7: Like do they streamline initiatives, are they going to step
- 10:58Speaker 7: up cost discipline or capital return or if it doesn't
- 11:01Speaker 7: work out, maybe they'd consider like big assets like Venmo.
- 11:05Speaker 7: You know, strategically, the performance doesn't inflect from that.
- 11:08Speaker 6: So what's the fintech landscape like these Daystally, it seems
- 11:12Speaker 6: like it's very quickly evolving. Here, Just give us a
- 11:15Speaker 6: sense of the lay of the land airs ore. You
- 11:18Speaker 6: talk to anybody under the age of thirty, they ain't
- 11:20Speaker 6: got any cash in their pockets.
- 11:21Speaker 5: So what's the whole new world out there?
- 11:24Speaker 7: Yes, I'm with you that, which is why it was
- 11:26Speaker 7: quite interesting that they replaced Alex Chris is the CEO.
- 11:31Speaker 7: I think the landscape is intensely competitive. The two key
- 11:35Speaker 7: themes that are driving at the cutting edge of fintech
- 11:39Speaker 7: is the innovation around agentic payments, agentic commerce where paper
- 11:43Speaker 7: was showing up in a big way as well, and
- 11:45Speaker 7: stable coins, which is again like moving transactions on the blockchain.
- 11:51Speaker 7: And things are moving really fast, Paul, because as you
- 11:55Speaker 7: really pointed out, like nobody carries cash in their wallet.
- 11:58Speaker 7: The younger generations want transactions to happen in the flip
- 12:02Speaker 7: of a second. There is and you know, the base
- 12:05Speaker 7: at pitch software and AI has moved payments needs to
- 12:09Speaker 7: kind of keep pace with that. So and the regulatory
- 12:13Speaker 7: regime obviously has supported that as well. So there is
- 12:15Speaker 7: a lot going on, and I just worry that if
- 12:18Speaker 7: Peopal is going to get left behind.
- 12:21Speaker 5: Stay with us. More from Bloomberg Intelligence coming up after this.
- 12:28Speaker 1: You're listening to the Bloomberg Intelligence podcast. Catch us live
- 12:32Speaker 1: weekdays at ten am Eastern on Apple, Cocklay and Android
- 12:35Speaker 1: Auto with the Bloomberg Business app. Listen on demand wherever
- 12:38Speaker 1: you get your podcasts, or watch us live on YouTube.
- 12:42Speaker 5: Pepsi out with some numbers today.
- 12:44Speaker 6: The earnings beat estimates, But for me, the big thing
- 12:47Speaker 6: is Pepsi's going to cut De Rito's prices by as
- 12:50Speaker 6: much as fifteen percent to boost demand.
- 12:52Speaker 5: When you see that, I just can't remember.
- 12:54Speaker 3: Double did your price cut?
- 12:56Speaker 6: Well, I just don't think you remember the prices of
- 12:58Speaker 6: sieyes one.
- 13:00Speaker 5: When all the supply chain stuff happened. Okay.
- 13:03Speaker 6: I could see how they were jacking up prices because
- 13:05Speaker 6: a pandemic, but they don't come down after the stuff's over,
- 13:09Speaker 6: do they. I mean, it's not like an avocado, which
- 13:11Speaker 6: is a commodity.
- 13:12Speaker 3: I want to see this charted out what it looks like.
- 13:14Speaker 5: Yes, over time.
- 13:15Speaker 6: Ken Chay, senior consumer Products analyst, joins us here from
- 13:17Speaker 6: Bloomberg Intelligence. Ken talk to us about Pepsi again. Came
- 13:21Speaker 6: out with some earnings results and then some interesting topics
- 13:24Speaker 6: about pricing some of their products.
- 13:27Speaker 8: Yeah, Hi, Paul, Yeah, PepsiCo's numbers today, as you alluded to,
- 13:31Speaker 8: they beat their expectations by a little bit. But I
- 13:34Speaker 8: think the broad takeaway for investors from today is that
- 13:38Speaker 8: PepsiCo is committed to bringing better focus to this company.
- 13:43Speaker 8: You know, I've covered this company a long time and
- 13:45Speaker 8: it's it's primary competitors, Coca Cola, Cure, Doctor Pepper, you
- 13:49Speaker 8: can say, Primal Water Monster. How they different from PepsiCo
- 13:53Speaker 8: is the much more focused particularly specific categories. But PepsiCo,
- 13:59Speaker 8: with the urge of the activists urging them on, is
- 14:03Speaker 8: bringing more focus to this company. And what I mean
- 14:05Speaker 8: is they're rationalizing a lot of the SKUs that really
- 14:09Speaker 8: aren't contributing much. They're consolidating plans, they are bringing more
- 14:15Speaker 8: rationality to the trade spending. So when I hear things
- 14:19Speaker 8: that like, you know, cutting prices, that's tactical. That's just
- 14:22Speaker 8: a way to move the need a little bit with
- 14:24Speaker 8: near term sales. But I think the bigger picture is
- 14:27Speaker 8: to bringing more focus to this enterprise, and I think
- 14:29Speaker 8: that's what's behind a lot of the enthusiasm behind the
- 14:32Speaker 8: share price today, right.
- 14:33Speaker 2: I mean, investors are excited about it strategy as opposed
- 14:37Speaker 2: to just kind of moving forward with the way it's
- 14:39Speaker 2: always been. When it comes to those price cuts, though,
- 14:42Speaker 2: I wonder if this is going to spark any kind
- 14:44Speaker 2: of price war, will other snack makers feel the pressure
- 14:48Speaker 2: to also reduce prices, even if they've gone up quite
- 14:50Speaker 2: a bit since the pandemic.
- 14:53Speaker 8: That's possible, Scarlett. In the case of free too lay though,
- 14:56Speaker 8: they have such a dominant market share, and they have
- 14:59Speaker 8: like sixty percent of the market in the in the
- 15:01Speaker 8: measure channels, and when you have that much of a share,
- 15:05Speaker 8: you deserve a premium. Particularly with Petsico's direct store delivery system.
- 15:11Speaker 8: What that means is that they help their retailers much
- 15:14Speaker 8: more than a lot of their competitors, and that is
- 15:17Speaker 8: they actually go to the store quickly, respond to out
- 15:20Speaker 8: of stocks, they help you know, position the product, they
- 15:24Speaker 8: create the end caps in the in the store. They
- 15:27Speaker 8: do a lot more for the retailer than the competitors.
- 15:31Speaker 8: And so that's how they are helped to get premium pricing. So, yes,
- 15:35Speaker 8: they're rolling back some prices. You know, it's no secret
- 15:38Speaker 8: that price increases have been up quite a bit since
- 15:41Speaker 8: the pandemic, and a lot of it's cost driven. Uh
- 15:45Speaker 8: and and private label has encroached a little bit on
- 15:48Speaker 8: PepsiCo share. But to answer your question directly, they are
- 15:51Speaker 8: the dominant player. I would not expect them to give
- 15:54Speaker 8: back too much over time. And while their competitors may
- 15:59Speaker 8: cut price as well, I think retail would be alienating
- 16:03Speaker 8: consumers if they pushed too hard on Petsico's price increases
- 16:07Speaker 8: down the road.
- 16:09Speaker 5: I was just in the shop rate in Bellmart, New
- 16:10Speaker 5: Jersey yesterday. Lots of private label stuff on the shelves.
- 16:14Speaker 5: I mean, prominent shows.
- 16:15Speaker 3: How are you reaching for this?
- 16:16Speaker 5: I am in many cases. I am in many cases.
- 16:19Speaker 5: Ken talk to us about Elliott Management.
- 16:20Speaker 6: They've been in this company, they've owned this stock here
- 16:23Speaker 6: pushing for some change.
- 16:24Speaker 5: How much of an impact are they having.
- 16:28Speaker 8: I think on the margin there's an impact. Poll maybe
- 16:31Speaker 8: to the degree that Petsico is hastening. It's moved to
- 16:34Speaker 8: more focus, you know a lot of the things that
- 16:36Speaker 8: it's been doing all along, and that is upbringing their
- 16:40Speaker 8: portfolio with more functionality. This is some of the things
- 16:44Speaker 8: we talked about in the past. They're bringing more protein
- 16:47Speaker 8: to their mix, the poppy prebotic sodas, they're bringing i'm sorry,
- 16:52Speaker 8: more fiber, the probiotic sodus. They're bringing more protein by
- 16:56Speaker 8: restaging muscle milk, so bringing more value to to the beverages.
- 17:04Speaker 8: So they've always been doing that, but to your question,
- 17:07Speaker 8: Elliott is pushing them to do things like, Okay, you
- 17:10Speaker 8: can still do that, but also cut costs a little
- 17:13Speaker 8: more aggressively. You know, maybe maybe you don't need all
- 17:16Speaker 8: these plants, Maybe you can consolidate some. Maybe there's some SKUs,
- 17:19Speaker 8: you know, some products that aren't selling, well you can
- 17:21Speaker 8: roll those back. Be a little more nimble when it
- 17:25Speaker 8: comes to getting rid of some products that aren't winners,
- 17:28Speaker 8: because at the end of the day, you have to
- 17:29Speaker 8: grab as much shelf space as the retailer as possible,
- 17:33Speaker 8: and when you have products on the shelf that aren't moving,
- 17:35Speaker 8: you're not helping them, you know, with their business. So
- 17:38Speaker 8: be more a little more aggressive with that. So it's
- 17:41Speaker 8: helping and I think that's a positive thing for shareholders.
- 17:46Speaker 2: Is this a company that's going to have to separate
- 17:48Speaker 2: its drinks business from its back business.
- 17:51Speaker 8: Well, that's the age old question we've been talking about
- 17:54Speaker 8: for a while. And as I mentioned, if it can
- 17:57Speaker 8: prove to the market that this increased focus that they
- 18:00Speaker 8: have with just doing their you know, daily business or
- 18:03Speaker 8: running these operations, they can improve them. I think the
- 18:07Speaker 8: heat will be off for them to go to the
- 18:09Speaker 8: draconian measure of breaking up food and beverages. That's always,
- 18:13Speaker 8: you know, the wild card I think down the road,
- 18:16Speaker 8: and I think will be well received by the market
- 18:17Speaker 8: quite frankly, but I don't think it's necessary at this point.
- 18:21Speaker 6: What are you consumer product products companies telling you ken
- 18:25Speaker 6: about just the consumer out there?
- 18:29Speaker 8: Well, Altria just the other day. I mean, it's a
- 18:31Speaker 8: different market with cigarettes, you know. They noted that consumers
- 18:34Speaker 8: are still hesitant in paying up for premium products, and
- 18:37Speaker 8: the cigarettes mentioned isn't the same category as salty snacks,
- 18:42Speaker 8: but they do note that consumers are reaching for the
- 18:46Speaker 8: private label, the low priced alternative, more than they've done
- 18:49Speaker 8: in the past, and so the extent of that that
- 18:51Speaker 8: carries over to you know, sacks and beverages. I can
- 18:54Speaker 8: see some parallel lines here, and as more companies, uh
- 18:58Speaker 8: you know, release their numbers, I think that could be
- 19:00Speaker 8: a common theme here that private labels encroaching and maybe
- 19:04Speaker 8: there needs to be some more deceleration in the uh,
- 19:07Speaker 8: you know, reliance on price increases to stimulate sales growth.
- 19:13Speaker 5: Stay with us. More from Bloomberg Intelligence coming up.
- 19:19Speaker 1: You're listening to the Bloomberg Intelligence podcast. Catch us live
- 19:23Speaker 1: weekdays at ten am Eastern on Apple, Cocklay and Android
- 19:26Speaker 1: Auto with the Bloomberg Business App. Listen on demand wherever
- 19:30Speaker 1: you get your podcasts, or watch us live on YouTube.
- 19:34Speaker 3: It is earning season.
- 19:35Speaker 2: We're knee deep in it and big pharma is reporting,
- 19:37Speaker 2: and let's start off with Pfizer. The shares are down
- 19:40Speaker 2: about three point four percent. Pfizer is trying to break
- 19:44Speaker 2: into the anti obesity market, the you know, the diet pills,
- 19:49Speaker 2: we don't call it die pills, weight loss waits, yes,
- 19:52Speaker 2: and not getting very far in it. They've made some big,
- 19:54Speaker 2: big investments and it's time now to see how it's
- 19:57Speaker 2: all paying off or perhaps not. Sam Fizzelli is out
- 20:00Speaker 2: our director of research for Global Industries and senior pharmaceuticals analysts,
- 20:03Speaker 2: and he's in London right now with a jacket that
- 20:06Speaker 2: says this.
- 20:08Speaker 5: BI drug Boss. BI is Bloomberg Intelligence.
- 20:11Speaker 3: And he's the drug Boss.
- 20:12Speaker 5: And he's the drug boss all right.
- 20:14Speaker 9: So your producer told me I can wear it, so
- 20:18Speaker 9: if I shouldn't have, a very good friend of BI
- 20:21Speaker 9: got this for me. So I thought that these ones
- 20:23Speaker 9: I should hear it otherwise that's my boring jacket on next.
- 20:26Speaker 2: No, no, no, we welcome it, mister drug boss, So
- 20:29Speaker 2: thank you for joining us again.
- 20:30Speaker 3: Sam.
- 20:31Speaker 2: Let's talk a little bit about these visor results because
- 20:34Speaker 2: it feels like it's the you know, people aren't paying
- 20:37Speaker 2: that much attention to what happened in the fourth quarter
- 20:39Speaker 2: or even the reaffirmed full year guidance. It's all about,
- 20:42Speaker 2: you know, the latest data on the obesity drug from
- 20:46Speaker 2: met Sarah, which Vizer is purchasing.
- 20:49Speaker 9: Yeah, yeah, so look they paid ten point one billion
- 20:51Speaker 9: dollars for this and the share price is down three percent.
- 20:54Speaker 9: If it all to do with that, there is it
- 20:55Speaker 9: people being reminded again that the next three four years
- 20:59Speaker 9: there's a may headwind from generic drugs coming for there
- 21:03Speaker 9: some of the key products on the market eyebrands, ex Standy,
- 21:08Speaker 9: et cetera. So that's partly the issue. And you know,
- 21:11Speaker 9: in order to deal with that, you need assets and
- 21:14Speaker 9: drugs that are going to try and hopefully fill the gap.
- 21:17Speaker 9: And maybe this is the problem with the data. The
- 21:19Speaker 9: thing is, we've looked at the data, as you know,
- 21:22Speaker 9: we have very deep obousity analysis. We've looked at the
- 21:24Speaker 9: data and it's not terrible. But as I said the
- 21:28Speaker 9: other day when Rash reported there's some numbers, I think
- 21:31Speaker 9: folks are getting over this percentage here, percentage there. You
- 21:36Speaker 9: can only to the point going forward you can't, I
- 21:38Speaker 9: mean unless you give out somebody that are thirty forty weights,
- 21:41Speaker 9: which of course nobody wants. So this is getting to
- 21:44Speaker 9: a point where now it comes to the nuance, and
- 21:47Speaker 9: unfortunately we don't have a lot of the nuance that
- 21:49Speaker 9: we need to know about this data set tolerability. And
- 21:53Speaker 9: it is good because it's a once monthly injection after
- 21:55Speaker 9: the first few weeks, so it's well set up, but
- 21:59Speaker 9: the market obviously doesn't like it because they're not getting
- 22:01Speaker 9: enough information about how good actually it is. Sam.
- 22:04Speaker 6: It seems like if you want to be an investor
- 22:06Speaker 6: in big cap farming, you really have to be a
- 22:09Speaker 6: stock picker. I've got stocks like Pfizer and Bristol on
- 22:11Speaker 6: a trailing twelve month basis that are down. But I've
- 22:15Speaker 6: got stocks like Johnson and Johnson and Eli Lilly and abby.
- 22:18Speaker 5: V They're are big.
- 22:20Speaker 6: And is that just because they've got the right portfolio
- 22:22Speaker 6: of drugs and the others don't.
- 22:25Speaker 9: Entirely entirely about that what is. What you don't want
- 22:29Speaker 9: is looking into the abyss of generic drugs coming for
- 22:32Speaker 9: your big earners with no obvious pipeline versus, let's take
- 22:37Speaker 9: it Johnson and Johnson. In this case, they have a
- 22:40Speaker 9: phenomenal set of drugs for the multiple miloma space or
- 22:46Speaker 9: a whole you know, other oncology spaces. This is the powerhouse.
- 22:49Speaker 9: And of course they've also still got the other divisions
- 22:52Speaker 9: medical devices growing quite nicely so and no massive I mean,
- 22:58Speaker 9: there's one that's coming up, big hole that's coming in
- 23:01Speaker 9: terms of generics, but they've still got these things that
- 23:04Speaker 9: are growing at phenomenal speed. And one of their drugs, Dolllects,
- 23:08Speaker 9: is very close to twenty billion dollars and that's just
- 23:11Speaker 9: one indication in multiple myloma. So they've done everything right
- 23:14Speaker 9: in that case, and that's what the market likes.
- 23:17Speaker 2: So in other words, Sam, this is something that can
- 23:19Speaker 2: be managed. The fact that Pfiser hasn't managed this well
- 23:23Speaker 2: raises a lot of questions here, because I mean it's
- 23:26Speaker 2: not like just one day they woke up and oh,
- 23:28Speaker 2: you know, there's suddenly a lot of competition for some
- 23:31Speaker 2: of their best selling drugs, or people are no longer
- 23:34Speaker 2: paying up for COVID treatments COVID vaccines. In terms of management,
- 23:38Speaker 2: do investors need to question whether adviser has right management
- 23:42Speaker 2: in place?
- 23:44Speaker 8: Yeah?
- 23:44Speaker 9: I mean, look, this is a tough game, right, not
- 23:48Speaker 9: a game of course, this is a very tough set
- 23:51Speaker 9: of issues to deal with. Creating pipeline takes a lot
- 23:56Speaker 9: of effort. Let's take Eli Lilly. For years, nobody was
- 23:59Speaker 9: paid too much attention to their potential margin expansion that
- 24:02Speaker 9: was coming and they were arguing for it, et cetera.
- 24:05Speaker 9: Maybe they were lucky they hit on these obesity drugs
- 24:08Speaker 9: you get. Ask for Zeneca. It took quite a lot
- 24:10Speaker 9: of pain for Pascal Soio. You should write that ship
- 24:14Speaker 9: when he took it. So management's part of it. Then
- 24:17Speaker 9: you need to be lucky. You cannot have just one
- 24:21Speaker 9: or the other and pipeline. You know, we'll see what
- 24:24Speaker 9: Filer shows us over time. They have assets that are
- 24:26Speaker 9: in earlier development that we need to start seeing their fruit.
- 24:29Speaker 6: Hey, Sam John from the Jersey Short times in any
- 24:32Speaker 6: ass will AI have a meaningful impact on coming up
- 24:35Speaker 6: with new drugs, new therapies?
- 24:36Speaker 5: Is this going to really be a game changer?
- 24:39Speaker 9: It will be. You need mich Colle Andrew galler on,
- 24:42Speaker 9: because it's done a lot of work on this, and yes,
- 24:45Speaker 9: the answer is it will be depending on what area
- 24:47Speaker 9: you're looking at. We think it can cut the time
- 24:50Speaker 9: to get a drug to market by a year or
- 24:52Speaker 9: so in the next five to ten years. By the
- 24:56Speaker 9: fact that you could use it for doing much better
- 25:00Speaker 9: work in the very early stage, in the pre clinical stage,
- 25:02Speaker 9: you can shave some serious time of that. We talk
- 25:05Speaker 9: to a lot of hospitals, a lot of clinicians, a
- 25:07Speaker 9: lot of scientists, and they're all super excited by that.
- 25:10Speaker 9: One of the key things that people are using is
- 25:12Speaker 9: this thing called Alpha fold that was developed by Google's
- 25:15Speaker 9: Deep Mind, and that is really making a difference to
- 25:17Speaker 9: people hunting for drugs at that early stage.
- 25:21Speaker 1: This is the Bloomberg Intelligence podcast, available on Apple, Spotify,
- 25:26Speaker 1: and anywhere else you get your podcasts. Listen live each
- 25:29Speaker 1: weekday ten am to noon Eastern on Bloomberg dot Com,
- 25:33Speaker 1: the iHeartRadio app, tune In, and the Bloomberg Business app.
- 25:37Speaker 1: You can also watch us live every weekday on YouTube
- 25:41Speaker 1: and always on the Bloomberg terminal